The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo
Open accessAbstract
Human epidermal growth factor receptor 2 (HER2) is overexpressed in >20% of breast cancers. Dimerization of HER2 receptors leads to the activation of downstream signals enabling the proliferation and survival of malignant phenotypes. Owing to the high expression levels of HER2, combination therapies are currently required for the treatment of HER2 + breast cancer. Here, we designed non-toxic transformable peptides that self-assemble into micelles under aqueous conditions but, on binding to HER2 on cancer cells, transform into nanofibrils that disrupt HER2 dimerization and subsequent downstream signalling events leading to apoptosis of cancer cells. The phase transformation of peptides enables specific HER2 targeting, and inhibition of HER2 dimerization blocks the expression of proliferation and survival genes in the nucleus. We demonstrate, in mouse xenofraft models, that these transformable peptides can be used as a monotherapy in the treatment of HER2 + breast cancer. HER2-targeting peptide-based micelles transform into nanofibrils on binding to HER2 on cancer cells, triggering cancer cell apoptosis and tumour death in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Liquid phase condensation in cell physiology and disease
Shin, Y., & Brangwynne, C. P. (2017) · Science · doi:10.1126/science.aaf4382 · Cited by 4,152
Olayioye, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,434
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006) · Cell · doi:10.1016/j.cell.2006.05.013 · Cited by 1,650
Webber, M. J., Appel, E. A., Meijer, E. W., & Langer, R. (2016) · Nature Materials · doi:10.1038/nmat4474 · Cited by 1,605
The discovery of receptor tyrosine kinases: targets for cancer therapy
Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Gravalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,184
Pathway complexity in supramolecular polymerization
Korevaar, P. A., George, S. J., Markvoort, A. J., Smulders, M. M. J., Hilbers, P. A. J., Schenning, A. P. H. J., De Greef, T. F. A., & Meijer, E. W. (2012) · Nature · doi:10.1038/nature10720 · Cited by 1,077
Supramolecular systems chemistry
Mattia, E., & Otto, S. (2015) · Nature Nanotechnology · doi:10.1038/nnano.2014.337 · Cited by 1,018
Cited by
Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment
Liu, R., Luo, C., Pang, Z., Zhang, J., Ruan, S., Wu, M., Wang, L., Sun, T., Li, N., Han, L., et al. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.05.032 · Cited by 516
Self-citationThe tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives
Sun, R., Xiang, J., Zhou, Q., Piao, Y., Tang, J., Shao, S., Zhou, Z., Bae, Y. H., & Shen, Y. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114614 · Cited by 433
Shedding Light on Extracellular Vesicle Biogenesis and Bioengineering
Teng, F., & Fussenegger, M. (2021) · Advanced Science · doi:10.1002/advs.202003505 · Cited by 382
Advanced bioactive nanomaterials for biomedical applications
Zhao, Y., Zhang, Z., Pan, Z., & Liu, Y. (2021) · Exploration · doi:10.1002/exp.20210089 · Cited by 357
Ma, W., Yang, Y., Zhu, J., Jia, W., Zhang, T., Liu, Z., Chen, X., & Lin, Y. (2022) · Advanced Materials · doi:10.1002/adma.202109609 · Cited by 300
Metadata
- Authors
- Zhang, L., Jing, D., Jiang, N., Rojalin, T., Baehr, C. M., Zhang, D., Xiao, W., Wu, Y., Cong, Z., Li, J. J., Li, Y., Wang, L., & Lam, K. S.
- Venue
- Nature Nanotechnology
- Published
- 2020-01-27
- Volume
- 15
- Issue
- 2
- Pages
- 145-153
- ISSN
- 1748-3387 (ISSN-L)
- 1748-3395
- OpenAlex
- W3001026887
- Cited by
- 270
- References
- 43
- FWCI
- 12.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo. https://app.cochat.ai/papers/10.1038/s41565-019-0626-4
- The paper
- Zhang, L., Jing, D., Jiang, N., Rojalin, T., Baehr, C. M., Zhang, D., Xiao, W., Wu, Y., Cong, Z., Li, J. J., Li, Y., Wang, L., & Lam, K. S. (2020). Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo. Nature Nanotechnology. https://doi.org/10.1038/s41565-019-0626-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.